2025-11-12 11:19 |
Detailed record - Similar records
|
2025-11-12 11:17 |
Detailed record - Similar records
|
2025-11-12 11:17 |
Detailed record - Similar records
|
2025-11-12 11:15 |
[DZNE-2025-01255]
Journal Article
Huber, H. ; Arranz, J. ; Arslan, B. ; et al
Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome.
Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. [...]
Restricted: PDF PDF (PDFA);
Detailed record - Similar records
|
2025-11-12 11:13 |
Detailed record - Similar records
|
2025-11-11 18:08 |
Detailed record - Similar records
|
2025-11-11 09:16 |
Detailed record - Similar records
|
2025-11-11 09:15 |
Detailed record - Similar records
|
2025-11-10 09:56 |
Detailed record - Similar records
|
2025-11-10 09:45 |
[DZNE-2025-01248]
Journal Article
Planche, V. ; Mansencal, B. ; Fonov, V. ; et al
Anatomical progression of genetic frontotemporal lobar degeneration across the lifespan.
The recent development of brain charts for the human lifespan offers an ideal modelling framework for pathologies such as genetic frontotemporal lobar degeneration (FTLD) which likely involve both neurodevelopmental and neurodegenerative processes over a lifetime. We have therefore combined this new methodological approach with MRI data from asymptomatic and symptomatic subjects, carrying C9orf72, MAPT or GRN mutations from the Genetic FTD Initiative (GENFI) and the ARTFL-LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) study. [...]
Restricted: PDF PDF (PDFA);
Detailed record - Similar records
|
|
|